ALK – Epidemiology – Mature Markets Data
Clarivate Epidemiology’s coverage of anaplastic lymphoma kinase (ALK) comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of ALK for each country, as well as annualized case counts projected to the national population.
The patient populations are forecast over a period of 10 years for the countries covered in this report. In addition to forecasting incident patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
Clarivate Epidemiology’s ALK forecast will answer the following questions:
- How will improvements in survival change the number of people living with a diagnosis of ALK-mutated cancer?
- Of all people diagnosed with ALK-mutated cancer, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ALK over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 44 ALK-mutated cancer populations, including the following:
- Diagnosed incident cases of ALK-mutated cancer by primary tumor site.
- Diagnosed incident cases of ALK-mutated cancer by metastatic status.
- Diagnosed first-line drug-treatable population of ALK-mutated cancer by site of primary tumor.
- … and many more (details available on request).
Note: Coverage may vary by country.
Table of contents
- ALK - Epidemiology - Mature Markets Data
- Epidemiology Data
- Methods
- Literature review (studies included in/excluded from the analyses of ELM4-ALK-mutated cancers)
- Diagnosed incident cases of ALK-mutated cancers
- Diagnosed incident cases of ALK-mutated breast cancer
- Diagnosed incident cases of ALK-mutated colorectal cancer
- Diagnosed incident cases of ALK-mutated NSCLC
- Diagnosed incident cases of ALK-mutated NSCLC adenocarcinoma
- Diagnosed incident cases of ALK-mutated renal cell carcinoma
- Diagnosed incident cases of ALK-mutated thyroid carcinoma
- Diagnosed incident cases of recurrent ALK-mutated cancer
- Diagnosed incident cases of first-line drug-treatable ALK-mutated cancer
- Risk / protective factors applied to disease forecast models
- Reference Materials
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.